Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
$9.13
-$0.70(-11.71%)
At close: 4:00 PM EST
$9.13
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$2.83 - $10.35
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.02M
Market Cap
$911.60M
Enterprise Value$450.71M
Total Cash (Recent Filing)$173.23M
Total Debt (Recent Filing)$42.44M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Nov 05, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding88,677,060
10 Day Avg. Volume1,303,096
30 Day Avg. Volume1,024,700
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue5.61
Enterprise Value/Gross Profit17.84
Enterprise Value/Ebitda-5.58
Forecast
1Y Price Target
$7.21Price Target Upside-21.03% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Test GrowthPSNL drove strong +59% q/q growth of its clinical tests with its partner Tempus and reaffirmed its goal to obtain two Medicare coverage determinations by YE'25.
Minimal Residual Disease TestingMinimal residual disease testing is seen as PSNL's key value creator, with the 'Win in MRD' strategy remaining on track.
Reimbursement ApplicationsIf all reimbursement applications receive positive decisions, they bode well for sustained revenue growth over the long term.
Bears Say
Pharma Services WeaknessPSNL specifically called out softness in the translational side of its pharma services business, including from Moderna.
Revenue GuidancePSNL's 2Q25 revenue missed consensus and management lowered their 2025 revenue guidance.
Sales And Revenue MissThe company reported total revenues of $17.2M, below the consensus estimate of $20.1M.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $2.83 and its highest was $10.35 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $911.60M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Nov 05, 2025 which is in 17 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Aug 05, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.01.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Overvalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.28.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 88,677,060 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -21.986%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
Personalis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.21 (-21.03% Downside)
$7.21 (-21.03% Downside)
Blogger Sentiment
Bullish
PSNL Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 238.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.61%
12-Months-Change
Fundamentals
Return on Equity
-60.26%
Trailing 12-Months
Asset Growth
39.45%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. (PSNL) is a biotechnology company that specializes in providing advanced genomic sequencing and analysis services. The company operates primarily within the healthcare sector, focusing on personalized medicine and genomic data analysis. Personalis's core products include its comprehensive genomic profiling solutions that enable precision oncology, allowing for tailored treatment plans based on an individual’s unique genetic makeup. By leveraging cutting-edge technology and proprietary algorithms, Personalis aims to improve patient outcomes and facilitate the development of targeted therapies.
PSNL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with significant achievements in clinical adoption and potential growth opportunities in MRD, yet faced challenges with revenue decline, biopharma project delays, and gross margin pressures. The company remains confident about future reimbursement outcomes and growth potential.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$7.21
▼(-21.03% Downside)
Technical Analysis
Ownership Overview
7.42% Insiders
7.34% Mutual Funds
46.47% Other Institutional Investors
23.22% Public Companies and
Individual Investors